Pharmaceutical care for patients with type 2 diabetes mellitus
Diabetes Mellitus (DM) is a chronic, degenerative disease that affects millions of people worldwide. In Brazil, the disease is linked to an increase in mortality in the adult population and a reduction in the quality of life of diabetic patients due to its complications. Based on this premise, this...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | Brasil |
| Institución: | Editora JRG |
| Repositorio: | Revista JRG de Estudos Acadêmicos |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs2.revistajrg.com:article/1440 |
| Acceso en línea: | http://revistajrg.com/index.php/jrg/article/view/1440 |
| Access Level: | acceso abierto |
| Palabra clave: | Cuidados Farmacêuticos; Diabetes Mellitus tipo 2; Intervenção Farmacêutica; Marcadores Bioquímicos; Tratamento. Pharmaceutical Care; Type 2 Diabetes Mellitus; Pharmaceutical Intervention; Biochemical Barkers; Care. |
| Sumario: | Diabetes Mellitus (DM) is a chronic, degenerative disease that affects millions of people worldwide. In Brazil, the disease is linked to an increase in mortality in the adult population and a reduction in the quality of life of diabetic patients due to its complications. Based on this premise, this study aims to analyze the importance of pharmaceutical care in adhering to treatment and reducing the complications that can occur in patients with type 2 DM. To this end, an integrative review study of randomized clinical trials was carried out using the BVS, PubMed and SciELO databases, whose survey of publications was carried out in the months of July to September 2023, considering the time frame 2010 to 2023, using the descriptors: pharmaceutical care, Type 2 Diabetes Mellitus; use of medications; hypoglycemic agents and adherence to drug treatment. With this in mind, 1,307 articles were identified, from which a sample of 11 publications was selected, according to the following inclusion criteria: open access studies that addressed pharmaceutical intervention in patients with type 2 DM and studies with biochemical indicators. Finally, the following pharmaceutical care was identified in the selected sample: guidance on the correct use of medication, promotion of healthy lifestyles, telephone consultations, group education, home visits, assessment of pharmacological and non-pharmacological needs, personalized care, patient counseling, prescription review, referral to other health professionals, collection of clinical and laboratory data to assess glycemic levels and adherence to treatment. In addition, the studies showed, from the analysis of biochemical markers, Fasting Blood Glucose (FG) and Glycated Hemoglobin (HbA1c), positive results obtained through pharmaceutical intervention in controlling the glycemic indices of the participants in the research, which demonstrated greater adherence to treatment. |
|---|